Blackstone Explores Sale of ZO Skin Health for $2 Billion

Blackstone is exploring a potential sale of medical-grade skincare brand ZO Skin Health in a deal that could value the business at approximately $2 billion, according to a Reuters report. The divestment process comes as private equity firms continue to test appetite for high-margin consumer health assets.

The sale process is currently in its early stages, and the final valuation could shift depending on bidder interest and broader market conditions.

Advisors and Sale Structure

To manage the transaction, the investment firm has enlisted investment bankers at Citigroup and Raymond James. The advisory team is currently assembling marketing materials for prospective corporate buyers and rival private equity funds.

Financial sponsors frequently utilize dual-advisor setups for large asset sales to broaden the reach of the auction process and manage negotiations across different geographic regions. While deliberations are active, sources cited by Reuters noted that there is no guarantee a transaction will be finalized.

Company Background and Distribution Model

Dermatologist Dr. Zein Obagi founded ZO Skin Health in 2007. The company specializes in medical-grade skincare formulations rather than traditional over-the-counter retail products.

ZO Skin Health distributes its product portfolio primarily through physicians, licensed aestheticians, and other specialized skincare professionals. This professional-channel distribution model separates the brand from mass-market beauty labels, shielding it from direct competition on traditional retail shelves and typically commanding higher gross margins.

Blackstone Market Performance

In public market trading, Blackstone Inc. (NYSE: BX) closed at $129.07, marking a decline of 3.66% on the day, according to Finnhub market data.

The broader transaction pipeline remains a key focus for Blackstone as the firm looks to return capital to its investors through realizations across its large private equity portfolios. Skincare and wellness brands have historically attracted strong interest from both strategic conglomerates seeking to expand their beauty portfolios and private equity buyers looking for predictable cash flows in the consumer sector.